Estradiol is a Small Molecule owned by TherapeuticsMD, and is involved in 7 clinical trials, which were completed.

TX-004HR (TX-12004HR), an estradiol replaces the natural estrogen hormone and acts by binding to nuclear receptors in estrogen-responsive tissues. Estradiol freely enters into target cells and interacts with a cytoplasmic target cell receptor. Estradiol then enters the nucleus of the target cell and regulates gene transcription and formation of mRNA. The mRNA interacts with ribosomes and forms specific proteins that causes effect of estradiol upon the target cell.

The revenue for Estradiol is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Estradiol NPV Report.

Estradiol is currently owned by TherapeuticsMD.

Estradiol Overview

Estradiol (Imvexxy/ TX-004HR) is a hydroxysteroid derivative, acts as an anti-menopausal agent. It is formulated as soft gelatin capsules for intravaginal route of administration. Imvexxy is indicated for the treatment of moderate to severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

The drug candidate is also under development for the treatment of moderate to severe dyspareunia in Israel.

TherapeuticsMD Overview

TherapeuticsMD is an innovative pharmaceutical company. It develops products to address the unique changes and challenges women experience throughout the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company’s major products portfolio includes segesterone acetate and ethinyl estradiol, estradiol and progesterone capsules, prenatal vitamins, estradiol vaginal inserts. The company sells its products under the various brands name of VitamedMD, BocaGreenMD, Annovera, Bijuva, vitaPearl, vitaTrue, vitaMedMD RediChew Rx, vitaMedMD One Rx, FOLMAX, pur-DHA, FePlus, Plant Pure Omega-3 DHA and Imvexxy. TherapeuticsMD is headquartered in Boca Raton, Florida, the US.

The company reported revenues of (US Dollars) US$87 million for the fiscal year ended December 2021 (FY2021), an increase of 34% over FY2020. The operating loss of the company was US$139.8 million in FY2021, compared to an operating loss of US$155.5 million in FY2020. The net loss of the company was US$172.4 million in FY2021, compared to a net loss of US$183.5 million in FY2020. The company reported revenues of US$20.9 million for the third quarter ended September 2022, a decrease of 26.8% over the previous quarter.

Quick View – Estradiol

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Estradiol
Administration Pathway
  • Vaginal
Therapeutic Areas
  • Women’s Health
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.